Retroviral proteases and their roles in virion maturation
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
25816761
DOI
10.1016/j.virol.2015.03.021
PII: S0042-6822(15)00157-9
Knihovny.cz E-zdroje
- Klíčová slova
- Antiretroviral therapy, Aspartic protease, Gag, Human immunodeficiency virus, Maturation, Protease inhibitor, Resistance, Retrovirus, Virus structure,
- MeSH
- antivirové látky farmakologie MeSH
- proteasy chemie genetika metabolismus MeSH
- proteolýza MeSH
- Retroviridae enzymologie fyziologie MeSH
- substrátová specifita MeSH
- virion metabolismus MeSH
- virová léková rezistence MeSH
- virové proteiny chemie genetika metabolismus MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- antivirové látky MeSH
- proteasy MeSH
- virové proteiny MeSH
Proteolytic processing of viral polyproteins is essential for retrovirus infectivity. Retroviral proteases (PR) become activated during or after assembly of the immature, non-infectious virion. They cleave viral polyproteins at specific sites, inducing major structural rearrangements termed maturation. Maturation converts retroviral enzymes into their functional form, transforms the immature shell into a metastable state primed for early replication events, and enhances viral entry competence. Not only cleavage at all PR recognition sites, but also an ordered sequence of cleavages is crucial. Proteolysis is tightly regulated, but the triggering mechanisms and kinetics and pathway of morphological transitions remain enigmatic. Here, we outline PR structures and substrate specificities focusing on HIV PR as a therapeutic target. We discuss design and clinical success of HIV PR inhibitors, as well as resistance development towards these drugs. Finally, we summarize data elucidating the role of proteolysis in maturation and highlight unsolved questions regarding retroviral maturation.
Citace poskytuje Crossref.org
Viral proteases as therapeutic targets
Precursors of Viral Proteases as Distinct Drug Targets
In vitro methods for testing antiviral drugs
Inhibition of the precursor and mature forms of HIV-1 protease as a tool for drug evaluation